Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 20, 2025Frontiers in OncologyOpen Access

Outcomes and toxicity of concomitant radioimmunotherapy following PD-1 blockade for locally advanced and metastatic cutaneous squamous cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAri A. KassardjianCLColton J LadburyATAndrew Tam

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows radioimmunotherapy improves survival in locally advanced cutaneous squamous cell carcinoma, suggesting a safe approach with minimal toxicity.

Key Points

  • To evaluate the oncologic outcomes and safety profile of combining radioimmunotherapy with PD-1 blockade in advanced cutaneous squamous cell carcinoma.
  • Retrospective cohort study of patients treated with concurrent PD-1 blockade and radiation therapy
  • Patients stratified by locally advanced or metastatic status
  • Outcomes assessed included locoregional control, freedom from distant metastases, progression-free survival, and overall survival
  • Statistical analysis conducted using Kaplan-Meier and Fine-Gray competing risk survival analyses.
  • 1-year overall survival was 75.2%, with 2-year survival at 62.7%
  • Progression-free survival at 1 year was 59.8%, declining to 25.6% at 2 years
  • Locoregional control improved to 100% for locally advanced cSCC versus 56.3% for metastatic cases
  • Only one patient experienced grade 3 radiation dermatitis, indicating minimal toxicity.

Cite This Study

Kassardjian et al. (2025) studied this question.

synapsesocial.com/papers/6924f07ac0ce034ddc34fd34https://doi.org/10.3389/fonc.2025.1679699
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world safety and efficacy of concurrent immunotherapy and thoracic chemoradiotherapy: A multi-institutional analysis.2024 · 1 citations
  2. 2The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results2024 · 10 citations
  3. 3A prospective study of definitive ChemoRadiation with ImmunOtherapy (CRIO) in locally or regionally advanced, unresectable cutaneous squamous cell carcinoma2026
  4. 4Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma2024 · 32 citations
  5. 5Radiotherapy and immunotherapy for advanced cancers: A meta-analysis of dose, sequencing, and survival patterns.2026